Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Diabeloop develops closed-loop insulin delivery algorithms that adapt automatically to each person with type 1 diabetes. Founded in 2015 in Grenoble as a spin-out of the CEA research centre, its software drives certified medical devices in Europe. The system personalises dosing decisions from continuous glucose data.
News
Diabeloop and ViCentra Launch Smartphone-Controlled DBLG2 System Integrated with Kaleido Insulin Patch Pump and Dexcom G7 CGM, Now Open for Prescription
GRENOBLE, France - July 10, 2026 - Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 Automated Insulin Delivery (AID) system, fully integrated with ViCentra's Kaleido insulin patch pump and Dex
Read more
Report
Diabeloop Unveils New DBLG2 Demo App: Experience the Future of Automated Insulin Delivery Simulation
GRENOBLE, France - June 30, 2026 - Diabeloop, a pioneer in therapeutic AI, today announced the launch of a new, highly anticipated tool: the DBLG2 Demo App. Designed to make the future of diabetes management accessible to everyone, the DBLG2 Demo app is a
Read more
Report
Diabeloop Announces CE Marking and Gradual Launch of the New DBLG2 System, Integrated with Dexcom G7 CGM and ViCentra's Kaleido Insulin Patch Pump.
GRENOBLE, France - Diabeloop today announced CE marking approval and the gradual European launch of its latest Automated Insulin Delivery (AID) system, DBLG2, integrated with Dexcom G7 Continuous Glucose Monitoring (CGM) system. Available as a smartphone
Read more
Report
Diabeloop Heads to ATTD 2026: Exploring Physical Activity and Gender Dynamics in AID Systems
We are excited to announce that Diabeloop will be participating in the upcoming Advanced Technologies & Treatments for Diabetes (ATTD) 2026 conference next week. Our team will be presenting compelling new data focused on one of the most persistent challen
Read more
Report
Diabeloop DBLG2: FDA-Cleared and CE-Marked Advanced AID Algorithm Designed to manage unexpected glycemic excursions
Editor's Note: This release was updated on March 3rd, 2026 to more precisely reflect the FDA-cleared Intended Use and the specific design capabilities of the DBLG2 algorithm. Grenoble, France - March 3rd, 2026 - Diabeloop, a pioneer in therapeutic artific
Read more
Report
Pro access
Upgrade to see all 16 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.